Babadaei Mohammad Mahdi Nejadi, Hasan Anwarul, Vahdani Yasaman, Bloukh Samir Haj, Sharifi Majid, Kachooei Ehsan, Haghighat Setareh, Falahati Mojtaba
Department of Molecular Genetics, Faculty of Biological Science, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Department of Mechanical and Industrial Engineering, College of Engineering, Qatar University, Doha, Qatar.
J Biomol Struct Dyn. 2021 Jul;39(10):3771-3779. doi: 10.1080/07391102.2020.1767210. Epub 2020 May 20.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative representative of a severe respiratory illness resulted in widespread human infections and deaths in nearly all of the countries since late 2019. There is no therapeutic FDA-approved drug against SARS-CoV-2 infection, although a combination of anti-viral drugs is directly being practiced in some countries. A broad-spectrum of antiviral agents are being currently evaluated in clinical trials, and in this review, we specifically focus on the application of Remdesivir (RVD) as a potential anti-viral compound against Middle East respiratory syndrome (MERS) -CoV, SARS-CoV and SARS-CoV-2. First, we overview the general information about SARS-CoV-2, followed by application of RDV as a nucleotide analogue which can potentially inhibits RNA-dependent RNA polymerase of COVs. Afterwards, we discussed the kinetics of SARS- or MERS-CoV proliferation in animal models which is significantly different compared to that in humans. Finally, some ongoing challenges and future perspective on the application of RDV either alone or in combination with other anti-viral agents against CoVs infection were surveyed to determine the efficiency of RDV in preclinical trials. As a result, this paper provides crucial evidence of the potency of RDV to prevent SARS-CoV-2 infections.Communicated by Ramaswamy H. Sarma.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是一种严重呼吸道疾病的病原体，自2019年末以来在几乎所有国家导致了广泛的人类感染和死亡。目前尚无美国食品药品监督管理局（FDA）批准的针对SARS-CoV-2感染的治疗药物，尽管一些国家正在直接应用抗病毒药物组合。目前正在对多种广谱抗病毒药物进行临床试验评估，在本综述中，我们特别关注瑞德西韦（RVD）作为一种潜在抗病毒化合物针对中东呼吸综合征（MERS）-CoV、SARS-CoV和SARS-CoV-2的应用。首先，我们概述了SARS-CoV-2的一般信息，接着介绍了RDV作为一种核苷酸类似物的应用，它可能抑制冠状病毒的RNA依赖性RNA聚合酶。之后，我们讨论了SARS-CoV或MERS-CoV在动物模型中的增殖动力学，这与在人类中的情况有显著差异。最后，我们探讨了单独使用或与其他抗病毒药物联合使用RDV对抗冠状病毒感染的一些当前挑战和未来前景，以确定RDV在临床前试验中的有效性。结果，本文提供了RDV预防SARS-CoV-2感染效力的关键证据。由拉马斯瓦米·H·萨尔马传达。
